您現在的位置: > Language Tips > Audio & Video > Special Speed News  
 





  Once-daily pill could simplify HIV treatment
[ 2006-02-06 15:57 ]


I’m Steve Ember with the VOA Special English Health Report.


Myers Squibb and Gilead Sciences have combined many H.I.V. drugs into a single pill
Sometimes the best medicine is more than one kind of medicine. Malaria, tuberculosis and H.I.V./AIDS, for example, are all treated with combinations of drugs.

But that can mean a lot of pills to take. It would be simpler if drug companies combined all the medicines into a single pill, taken just once a day.

Now, two companies say they have done that for people just starting treatment for H.I.V., the virus that causes AIDS. The companies are Bristol-Myers Squibb and Gilead Sciences.

They have developed a single pill that combines three drugs currently on the market. Bristol-Myers Squibb sells one of them under the name Sustiva. Gilead combined the others, Emtriva and Viread, into a single pill in two thousand four.

Combining drugs involves more than technical issues. It also involves issues of competition if the drugs are made by different companies. The new once-daily pill is the result of what is described as the first joint venture agreement of its kind in the treatment of H.I.V.

In January the New England Journal of Medicine published a study of the new pill. Researchers compared its effectiveness to that of the widely used combination of Sustiva and Combivir. Combivir contains two drugs, AZT and 3TC. The researchers say that after one year of treatment, the new pill suppressed H.I.V. levels in more patients and with fewer side effects.

Gilead paid for the study. Professor Joel Gallant at the Johns Hopkins School of Medicine in Baltimore, Maryland, led the research. He is a paid adviser to Gilead and Bristol-Meyers Squibb as well as the maker of Combivir, GlaxoSmithKline.

GlaxoSmithKline reacted to the findings by saying that a single study is of limited value. It says the effectiveness of Combivir has been shown in each of more than fifty studies.

The price of the new once-daily pill has not been announced. But Gilead and Bristol-Myers Squibb say they will provide it at reduced cost to developing countries.

They plan in the next few months to ask the United States Food and Drug Administration to approve the new pill.

There are limits to who could take it because of the different drugs it contains. For example, pregnant women are told not to take Sustiva because of the risk of birth disorders.

Experts say more than forty million people around the world are living with H.I.V.

This VOA Special English Health Report was written by Cynthia Kirk. Read and listen to our reports at voaspecialenglish.com. I’m Steve Ember.

Vocabulary

 

 

 
 
 




主站蜘蛛池模板: 日本一区视频在线| 激情网站免费看| 国产精品va无码二区| 一二三四在线观看免费高清视频| 日韩黄色免费观看| 亚洲精品在线免费看| 美女在线免费观看| 国产成人免费手机在线观看视频 | jizz大全欧美| 日产精品卡一卡2卡三卡乱码工厂| 亚洲午夜无码久久| 狠狠躁日日躁夜夜躁2022麻豆| 国产a不卡片精品免费观看| 久草视频在线网| 国产视频久久久久| 一区二区三区日本视频| 日本xxxx裸体bbbb| 二代妖精在线观看免费观看| 欧美色欧美亚洲高清在线视频 | 色偷偷AV老熟女| 国产成人精品无码免费看| 97久久精品人人做人人爽| 少妇无码av无码专区线| 久久久久亚洲精品中文字幕| 有色视频在线观看免费高清在线直播| 亚洲熟妇AV乱码在线观看| 看免费的黄色片| 啊快点再快点好深视频免费| 靠逼软件app| 国产模特众筹精品视频| 57pao一国产成视频永久免费| 天天碰免费视频| 一级毛片完整版免费播放一区| 日本免费网站观看| 乱子伦农村xxxx视频| 欧美另类第一页| 亚洲欧美日韩成人网| 玩弄丰满少妇人妻视频| 十九岁日本电影免费完整版观看| 色偷偷成人网免费视频男人的天堂| 国产国产人成免费视频77777|